Journals / Ege Tıp Dergisi / 2011 / Cilt: 50 - Sayı: 2

Gastric carcinoid tumours

Mide karsinoid tümörleri

Pages
73–79
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review will focus on clinical and pathophysiological facets of gastric carcinoid tumours, summarizing recent data on their diagnosis and management.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gastric carcinoid tumours are rare, but are increasing in occurence.
📊
Key Findings & Data:Types 1 and 2 gastric carcinoid tumours are associated with hypergastrinaemia and usually have low metastatic potential.
💡
Conclusion & Impact:This review will focus on clinical and pathophysiological facets of gastric carcinoid tumours, summarizing recent data on their diagnosis and management.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gastric carcinoid tumours are rare, but are increasing in occurence. Gastric carcinoid tumors originate from enterochromaffin-like cells. The clinical presentation is often non-specific. Three subtypes of gastric carcinoid tumors were defined. Types 1 and 2 gastric carcinoid tumours are associated with hypergastrinaemia and usually have low metastatic potential. Type 3 gastric carcinoid tumours are not associated with hypergastrinaemia and have a higher potential for metastatic disease. Most of types 1 and 2 gastric carcinoid tumors are multifocal, however type 3 gastric tumors are often solitary tumors. The development of a gastric carcinoid tumor has been responsible for many factors such as gastrin, genetic factors growth factors and matrix regulating proteins. This review will focus on clinical and pathophysiological facets of gastric carcinoid tumours, summarizing recent data on their diagnosis and management.

Özet

Mide karsinoid tümörleri nadir görülür ancak sıklığı artmaktadır. Mide karsinoid tümörler enterokromaffin benzeri hücrelerden köken alırlar. Klinik görünümü genellikle nonspesifikdir. Üç tip mide karsinoid tümörü tanımlanmıştır. Tip 1 ve 2 mide karsinoid tümörler hipergastrinemi ile ilişkilidir ve genellikle düşük metastaz potansiyeline sahiptirler. Tip III mide karsinoid tümörler hipergastrinemi ile ilişkisizdir ve yüksek metastaz potansiyeline sahiptirler. Tip 1 ve 2 mide karsinoid tümörler çoğunlukla multifokaldir, ancak tip 3 tümörler genellikle soliter tümörlerdir. Mide karsinoid tümörün gelişiminden gastrin, genetik faktörler, büyüme faktörleri ve matriks regülasyon proteinleri gibi birçok faktör sorumlu tutulmuştur. Biz bu derlemede mide karsinoid tümörlerinin kliniği ve patofizyolojisine odaklanarak, tanı ve tedavileri konusunda son yıllarda sağlanan gelismeleri özetledik.

🔖

Cite This Article

DEMİR, M., GEN, R., HİLMİ, A. (2011). Gastric carcinoid tumours. Ege Tıp Dergisi, Cilt: 50 - Sayı: 2, 73–79. https://ajindex.com/articles/222793

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Askanazy M. Zur Pathogenese der Magen-krebse und uber inhren gelegentlichen Ursprung aus angeboren epithelialen Keimen in der Magenwand. Deut Med Wochenschr 1923; 49: 49–51
  2. Hakanson R, Owman C, Sporrong B, Sundler F. Electron microscopic identification of the histamine-storing argyrophil (enterochromaffin-like) cells in the rat stomach. Zeitschrift fuer Zellforschung 1971; 122: 460–466
  3. Capella C,Vassallo G, Solcia E. Light and electron microscopic identification of the histamine-storing agyrophil (ECL) cell in murine stomach and of its equivalent in other mammals. Zeibschrift fuer Zellforschung 1971; 118: 68–70
  4. Borch K, Renvall H, Liedberg G, Andersen B.N. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986; 21: 357–363
  5. Modlin M, Lawton G.P, Tang L.H, et al. The Mastomys gastric carcinoid: Aspects of ECL cell function. Digestion 1994; 55(Suppl 3): 31–37
  6. Solcia E, Fiocca R, Sessa F et al. Morphology and natural history of gastric endocrine tumours. In: R. Hakanson and F. Sundler, Editors, The stomach as an endocrine organ, Elsevier, Amsterdam 1991: 473–498
  7. Modlin I.M, Lye K.D, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003; 12: 153-172
  8. Burkitt MD, Pritchard DM. Review article: Pathogenesis and Management of Gastric Carcinoid Tumours. Aliment Pharmacol Ther 2006; 24: 1305-20
  9. Hakanson R, Sundler F. Proposed mechanism of gastric carcinoids: the gastrin hypothesis. Eur J Clin Invest 1990: 20;65–71
  10. Cattan D, Roucayrol A.M, Launay J.M, el al. Circulating gastrin, endocrine cells, histamine content, and histidine decarboxylase activity in atrophic gastritis. Gastroenterology 1989; 97: 586–596
  11. Gilligan C.J, Lawton G.P, Tang L.H. et al. Gastric carcinoid tumors: The biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995; 90: 338–352
  12. Laüffer J, Modlin I, Hinoue T, et al. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats. Gastroenterology 1999; 116: 623–635
  13. Jensen R. Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477–488
  14. Chandrasekharappa SC, Guru SC, Manıckam P. Positional cloning the gene for multiple endocrine neoplasia type 1. Science 1997; 276:404-7
  15. Larsson C, Skogseid B, Oberg K et al. Mulitple endocrine neoplasia type 1 gene maps to